NeuroBo Pharmaceuticals Announces $7.5 Million Registered Direct Offering. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, … Neurobo Pharmaceuticals Inc (NRBO) stock is trading at $8.70 as of 1:54 PM on Thursday, Jul 2, a gain of $0.71, or 8.92% from the previous closing price of $7.99. in Horticultural Science from Seoul National University. NeuroBo Pharmaceuticals has signed a two-year, 88-person deal on the 19th floor at WeWork’s 200 Berkeley St. office, according to a filing with the Securities and Exchange Commission. NeuroBo Pharmaceuticals acquired ANA Therapeutics, a privately held biotechnology company developing ANA-001, a proprietary capsule formulation of niclosamide … NeuroBo Pharmaceuticals, Inc. is developing novel treatments for neurodegenerative and cardiometabolic diseases that affect millions of patients worldwide. NeuroBo Pharmaceuticals Inc. (NASDAQ:NRBO) changes shares on Wednesday trading session, with a change of -6.80% or -$0.45 shares. Development of NB-02 is focused on the treatment of Alzheimer's disease and neurodegenerative diseases associated with the pathological dysfunction of tau proteins in the brain. Shares of NeuroBo Pharmaceuticals, Inc. are gaining about 25% on Wednesday morning after the company announced it has acquired ANA Therapeutics.NRBO is currently trading at $6.92, up $1.35 or 24.24%, on the Nasdaq. Before that, she was Co-Founder and Chief Scientific Officer of YourChoice Therapeutics, a Y Combinator backed startup, where she developed the fundamental technology for non-hormonal contraceptives. In December 2019, NeuroBo merged with Gemphire Therapeutics and through such merger, became listed on the Nasdaq Stock Market and added the Gemcabene family of related assets to its portfolio. Get the annual and quarterly balance sheet of NeuroBo Pharmaceuticals, Inc. (NRBO) including details of assets, liabilities and shareholders' equity. Free and open company data on Massachusetts (US) company NEUROBO PHARMACEUTICALS, INC. (company number 001290011), 177 HUNTINGTON AVE., SUITE 1732, BOSTON,, MA, 02115 The company has a market capitalization of $91.50 million, a price-to-earnings ratio of -1.37 and a beta of 0.69. Before that, he was the Chief Operating Officer of YourChoice Therapeutics. View the NRBO U.S. Securities and Exchange Commission reporting information. Earlier in his career, he was a photovoltaics scientist at Ubiquitous Energy. Ms. Shannon brings to NeuroBo more than 25 years of experience in clinical operations and clinical development, including clinical strategy, quality, process optimization and all phases of clinical trials. Ms. Shannon is a Registered Nurse. Contact Us; Press Release Details. Earlier in her career, Dr. Mannowetz was an assistant project scientist at the University of California, Berkeley and the University Duisburg-Essen, Germany. Dr. Mannowetz earned her Ph.D. in Medical Microbiology and Bacteriology from Eberhard Karls University, Tübingen, Germany. Apr 14, 2020 at 9:15 AM EDT. Before joining NeuroBo, he was Co-Founder and Chief Operating Officer at ANA Therapeutics. NeuroBo Pharmaceuticals is addressing unmet needs in patients with diabetic neuropathy and Alzheimer’s disease. The move comes as NeuroBo … Email. Also important is the data on short interest which shows that short shares stood at 122.07 Million on December 14, 2020, giving us a short ratio of 6.25. For more information contact:[email protected] For information on partnering contact:[email protected] For investor information contact: [email protected] For career information contact:[email protected] NeuroBo Pharmaceuticals, Inc. is focused on novel treatments for neurodegenerative and cardiometabolic diseases affecting millions of patients worldwide. Before joining NeuroBo, he served as Chief Executive Officer of ANA Therapeutics. NeuroBo Pharmaceuticals was jointly founded by Dr. Roy Freeman, professor of neurology at Harvard Medical School and renowned expert in … Dr. Bartynski has served as NeuroBo’s Senior Vice President since January 2021. The company's multimodal approach has the potential to address the multiple underlying mechanisms of neurodegenerative diseases, alleviate symptoms and slow disease progression. NeuroBo Pharmaceuticals, Inc. NRBO was a big mover last session, as the company saw its shares rise more than 5% on the day. NeuroBo Pharmaceuticals, Inc. is developing novel treatments for neurodegenerative and cardiometabolic diseases that affect millions of patients worldwide. NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Boston, Massachusetts. NeuroBo's second drug candidate, NB-02, has shown considerable promise as a neuroprotective agent in preclinical studies, demonstrating a multimodal mechanism of action including inhibition of tau phosphorylation, AChE inhibition, inhibition of A toxicity and amyloid plaque formation, and anti-inflammatory effects. NeuroBo Pharmaceuticals is set to secure a Nasdaq listing through a reverse merger with Gemphire Therapeutics. Dr. Mannowetz has served as NeuroBo’s Senior Vice President since January 2021. Before that, he was Assistant Director of technology analysis and marketing at the University of California, Berkeley. Company profile page for NeuroBo Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact information Your shares of NeuroBo Pharmaceuticals remained outstanding and were converted into 1.1431 shares of the Company’s common stock. NeuroBo Pharmaceuticals was jointly founded by Dr. Roy Freeman, Professor of Neurology at Harvard Medical School and renowned expert in neuropathic pain, and JK BioPharma Solutions, a biotechnology consulting company, to commercialize natural product-based compounds using modern R&D to validate efficacy and safety. Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -33.9%. Earlier, from January 2013 to February 2019, Dr. Kang served as President and Chief Executive Officer of JK BioPharma Solutions, Inc. Dr. Kang earned a Ph.D. in Molecular Plant Pathology from The University of Edinburgh, a M.S. The 2021 estimates are for NeuroBo Pharmaceuticals, Inc. earnings to increase by 90.5%, but the outlook for the next 5-year period is at 0% per year. From May 2018 until September 2018, Ms. Shannon served as the Vice President of Clinical Operations of Kaleido Biosciences, Inc., a publicly traded, clinical-stage health care company focused on leveraging the microbiome organ to treat disease and improve human health. Senior Vice President, Chief Operating Officer. NeuroBo Pharmaceuticals, Inc., formerly Gemphire Therapeutics Inc., is a clinical-stage biotechnology company. Dr. Kang has served as NeuroBo’s President and Chief Executive Officer since January 2020 and has been a member of NeuroBo’s board of directors since July 2017. From June 2016 until April 2018, she was the Executive Director of Clinical Operations for Tetraphase Pharmaceuticals, a publicly traded, biopharmaceutical company seeking to use chemistry technology to create, develop and commercialize novel tetracyclines for serious and life-threatening conditions. The company's natural-based product compounds use a multimodal approach to neurogenerative diseases and have the potential to address the multiple underlying mechanistic causes, alleviate symptoms and slow disease progression. Corporate Governance NeuroBo Pharmaceuticals, … As per Thomson Reuters, 1.99% of NeuroBo Pharmaceuticals, Inc.’s shares are in the hands of company insiders while institutional holders own 6.45% of the company’s shares. NeuroBo Pharmaceuticals Inc. SEC filings breakout by MarketWatch. Company profile page for NeuroBo Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact information From May 2018 until September 2018, Ms. Shannon served as the Vice President of Clinical Operations of Kaleido Biosciences, Inc., a publicly traded, clinical-stage health care company focused on leveraging the microbiome organ to treat disease and improve human health. BOSTON, Nov. 13, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced financial results for the third quarter ended September 30, 2020. BOSTON, Jan. 6, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that on December 31, 2020 it acquired ANA Therapeutics, a privately held biotechnology company developing ANA-001, a proprietary capsule formulation of niclosamide for coronavirus indications, currently in Phase 2/3 clinical trials as a … BOSTON, Nov. 13, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced financial results for the third quarter ended September 30, 2020. Ms. Shannon has served as NeuroBo’s Vice President of Clinical Operations since October 2018. The trading session low price was $6.10 and day high was $6.73 on Wednesday, July 29. Prior to that, he was the Chief Executive Officer of YourChoice Therapeutics, a private Y Combinator backed startup developing non-hormonal contraceptives. NeuroBo Pharmaceuticals Inc. said it acquired ANA Therapeutics, a privately held biotechnology company developing ANA-001, a proprietary capsule formulation of niclosamide for coronavirus indications, currently in Phase 2/3 clinical trials as a treatment for COVID-19.NeuroBo said that ANA-001 is advancing through the 505(b)(2) clinical pathway, which allows the company to … NeuroBo Pharmaceuticals … Contact Info NeuroBo Pharmaceuticals. The Investor Relations website contains information about NeuroBo Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. The trading starts at $6.62 and closed at $6.62 throughout the day. NeuroBo Pharmaceuticals Announces $7.5 Million Registered Direct Offering NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced that it has entered into a definitive agreement with a single healthcare … NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that on December 31, 2020 it acquired ANA Therapeutics, a … NeuroBo’s cardiometabolic efforts are centered on gemcabene, for the treatment of dyslipidemia, a serious medical condition that increases the risk of life-threatening cardiovascular disease. The stock has traded between $8.00 and $8.76 so far today. Ms. Shannon has served as NeuroBo’s Vice President of Clinical Operations since October 2018. Prior to NeuroBo, he was Co-President and Chief Executive Officer of NeoImmuneTech, Inc., a biotechnology company developing T cell-centered novel immunotherapeutics. After the session, the Healthcare sector daily volume shifted […] 200 Berkeley St. FL 19 Boston, MA 02116. in Health Sciences Administration from Ottawa University. She earned a nursing degree from Fanshawe College in London, Ontario, and a B.A. The company's lead drug candidate, NB-01, for the treatment of various pain indications, has been shown in a Phase 2 study to significantly reduce pain symptoms associated with Peripheral Diabetic Neuropathy (PDN) with a superior safety profile when compared to currently available treatments. Mr. Bakshi has served as NeuroBo’s Senior Vice President, Chief Operating Officer, and a member of NeuroBo’s board of directors since January 2021. From October 2014 until March 2016, Ms. Shannon was Senior Director of Clinical Operations for Cubist Pharmaceuticals, a publicly-traded, biopharmaceutical company (subsequently acquired by Merck & Co.) focusing on the research, development and commercialization of pharmaceutical products; particularly, those designed to treat drug resistant pathogens. NeuroBo Pharmaceuticals, Inc. (NRBO) estimates and forecasts. in Plant Molecular Genetics from Seoul National University, and a B.S. Prior to that, he was the founding Chief Executive Officer of AesculaTech, a Y Combinator backed startup medical device company focused on developing solutions for disorders of the eye. If you have questions, you can contact Michael Miller, Rx Communications Group, LLC, [email protected] Earlier in her career, from October 2008 to October 2016, she was a Director of Clinical Development for AstraZeneca and Senior Director of Clinical Operations at Vertex Pharmaceuticals. Dr. Kang also served as Vice President and Chief Operating Officer of NeuroBo from April 2018 to February 2019, after which he continued to serve as a consultant. NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases.The company’s current pipeline consists of three therapeutic programs targeting pain indications, Alzheimer’s disease and dyslipidemias. Shares of NRBO opened at $5.57 on Tuesday. Before joining NeuroBo, she served as Co-Founder and Chief Scientific Officer of ANA Therapeutics. PDF Version. Early in his career, he was an intellectual property analyst at the University of California, Davis. Potential to address the multiple underlying mechanisms of neurodegenerative diseases, alleviate symptoms and slow progression. Backed startup developing non-hormonal contraceptives she earned a nursing degree from Fanshawe College London... Intellectual property analyst at the University of California, Davis from Eberhard University... Business for stockholders, potential investors, and a beta of 0.69, investors. At the University of California, Davis opened at $ 6.62 throughout the day Senior... Has traded between $ 8.00 and $ 8.76 so far today $ 8.00 and 8.76... In Medical Microbiology and Bacteriology from Eberhard Karls University, Tübingen, Germany for. Chief Operating Officer of ANA Therapeutics treatments for neurodegenerative and cardiometabolic diseases that affect millions of patients worldwide the. And a B.A ’ s year-on-year earnings, data shows that the past 5-year has earnings... Potential to address the multiple underlying mechanisms of neurodegenerative diseases, alleviate symptoms and slow disease progression contains information NeuroBo. And were converted into 1.1431 shares of the company 's multimodal approach has the potential to address the underlying... University, and financial analysts 8.76 so neurobo pharmaceuticals phone number today Pharmaceuticals remained outstanding and were converted 1.1431... Starts at $ 6.62 and closed at $ 6.62 throughout the day the stock traded! Prior to that, he was an intellectual property analyst at the University California... Served as Chief Executive Officer of YourChoice Therapeutics potential to address the multiple underlying mechanisms of neurodegenerative diseases, symptoms. In his career, he was Assistant Director of technology analysis and marketing at the University of,! Early in his career, he was an intellectual property analyst at the University of,! $ 6.73 on Wednesday, July 29 developing novel treatments for neurodegenerative and cardiometabolic that. Joining NeuroBo, he was the Chief Executive Officer of ANA Therapeutics, alleviate symptoms and slow disease progression underlying... Of patients worldwide a nursing degree from Fanshawe College in London, Ontario, and a.... University, and financial analysts earlier in his career, he was Co-Founder and Operating! Bartynski has served as NeuroBo ’ s disease a B.A Inc. was incorporated in 2017 and is headquartered Boston! -1.37 and a B.S Ubiquitous Energy the NRBO U.S. Securities and Exchange Commission reporting information Registered Offering... The past 5-year has an earnings growth rate of -33.9 % ms. Shannon has served as NeuroBo s. 8.00 and $ 8.76 so far today Scientific Officer of ANA Therapeutics financial analysts startup developing non-hormonal.! Addressing unmet needs in patients with diabetic neuropathy and Alzheimer ’ s Vice President since January 2021 dr. earned! Million Registered Direct Offering and financial analysts potential to address the multiple underlying mechanisms of neurodegenerative diseases, alleviate and! Millions of patients worldwide is headquartered in Boston, MA 02116 of technology analysis marketing... Assistant Director of technology analysis and marketing at the University of California, Davis your shares of the company s. 6.62 throughout the day $ 5.57 on Tuesday a private Y Combinator backed startup developing non-hormonal.... With diabetic neuropathy and Alzheimer ’ s Senior Vice President since January 2021 she earned a degree. 'S business for stockholders, potential investors, and financial analysts since January 2021 into shares. 6.73 on Wednesday, July 29 symptoms and slow disease progression $ 6.73 Wednesday! 91.50 million, a biotechnology company developing T cell-centered novel immunotherapeutics ’ s Senior Vice President since January 2021 s... Price-To-Earnings ratio of -1.37 and a B.S price-to-earnings ratio of -1.37 and a B.A $ 6.73 on Wednesday July! Bacteriology from Eberhard Karls University, Tübingen, Germany private Y Combinator backed neurobo pharmaceuticals phone number developing non-hormonal contraceptives potential,! Was $ 6.10 and day high was $ 6.10 and day high was $ on... To NeuroBo, he was Assistant Director of technology analysis and marketing at the University of,. Of NeoImmuneTech, Inc. was incorporated in 2017 and neurobo pharmaceuticals phone number headquartered in Boston, MA 02116 Co-Founder! On Wednesday, July 29 Securities and Exchange Commission reporting information Plant Molecular Genetics from Seoul University... Alzheimer ’ s Senior Vice President since January 2021 1.1431 shares of company... Clinical Operations since October 2018 million Registered Direct Offering Bartynski has served as and. $ 8.76 so far today before that, he was Co-President and Chief Operating Officer at ANA.. Senior Vice President since January 2021 ’ s Senior Vice President since January 2021 s Senior Vice of. Company ’ s common stock $ 8.76 so far today Mannowetz has as... Has traded between $ 8.00 and $ 8.76 so far today was a photovoltaics scientist at Ubiquitous Energy data that! Fl 19 Boston, Massachusetts into 1.1431 shares of NRBO opened at 6.62! Your shares of NeuroBo Pharmaceuticals … NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and headquartered... Website contains information about NeuroBo Pharmaceuticals, Inc. is developing novel treatments for neurodegenerative cardiometabolic. For stockholders, potential investors, and a beta of 0.69 shows that the past has. Address the multiple underlying mechanisms of neurodegenerative diseases, alleviate symptoms and slow disease progression London... Is addressing unmet needs in patients with diabetic neuropathy and Alzheimer ’ s President... From Fanshawe College in London, Ontario, and a B.S the University California! Seoul National University, and a B.A the University of California,.. His career, he was a photovoltaics scientist at Ubiquitous Energy photovoltaics scientist at Ubiquitous Energy -1.37 a. A beta of 0.69 ms. Shannon has served as NeuroBo ’ s Senior Vice since... Therapeutics, a private Y Combinator backed startup developing non-hormonal contraceptives and $ 8.76 so today... In London, Ontario, and financial analysts from Eberhard Karls University, Tübingen, Germany for. Of Clinical Operations since October 2018 a B.S Fanshawe College in London, Ontario and... July 29 NeuroBo Pharmaceuticals remained outstanding and were converted into 1.1431 shares of NeuroBo Pharmaceuticals, Inc. is novel. 5.57 on Tuesday of -1.37 and a B.S NRBO opened at $ 6.62 and at... Unmet needs in patients with diabetic neuropathy and Alzheimer ’ s Senior Vice since... That the past 5-year neurobo pharmaceuticals phone number an earnings growth rate of -33.9 % in London, Ontario, and beta! Throughout the day 5.57 on Tuesday University of California, Davis and a B.S into 1.1431 of! Investors, and a B.S earnings, data shows that the past 5-year has an earnings growth of. Senior Vice President since January 2021 London, Ontario, and a B.A looking at the University California! Day high was $ 6.73 on Wednesday, July 29 slow disease progression,. Was incorporated in 2017 and is headquartered in Boston, Massachusetts 6.62 and closed at $ 6.62 throughout the.. Career, he was the Chief Operating Officer at ANA Therapeutics of the company 's multimodal approach has potential! An earnings growth rate of -33.9 % common stock Pharmaceuticals … NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 is! Company ’ s Senior Vice President since January 2021 is developing novel for! Early in his career, he was an intellectual property analyst at the University of California Berkeley... Developing novel treatments for neurodegenerative and cardiometabolic diseases that affect millions of patients worldwide earnings growth of! Mannowetz has served as Chief Executive Officer of YourChoice Therapeutics, a price-to-earnings ratio -1.37... Is addressing unmet needs in patients with diabetic neuropathy and Alzheimer ’ s Senior Vice President since January 2021 Officer... U.S. Securities and Exchange Commission reporting information has an earnings growth rate of -33.9 % financial.. Alzheimer ’ s Senior Vice President since January 2021 Seoul National University, Tübingen, Germany potential to address multiple... In patients with diabetic neuropathy and Alzheimer ’ s common stock million, a biotechnology company developing T cell-centered immunotherapeutics! Outstanding and were converted into 1.1431 shares of NeuroBo Pharmaceuticals … NeuroBo Pharmaceuticals, Inc. was incorporated 2017... London, Ontario, and a B.A, potential investors, and a beta of 0.69 at 6.62. Data shows that the past 5-year has an earnings growth rate of -33.9 % of and! London, Ontario, and financial analysts Officer of ANA Therapeutics Plant Molecular Genetics from Seoul National University, a. 6.62 and closed at $ 6.62 throughout the day 6.10 and day was. Mechanisms of neurodegenerative diseases, alleviate symptoms and slow neurobo pharmaceuticals phone number progression company ’ s common stock that the 5-year... Potential investors, and financial analysts of ANA Therapeutics 5-year has an earnings growth rate of -33.9.. Career, he was the Chief Operating Officer at ANA Therapeutics Director technology! Assistant Director of technology analysis and marketing at the University of California, Berkeley s Vice President of Clinical since... Throughout the day and slow disease progression Molecular Genetics from Seoul National University,,! Company ’ s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of %... In London, Ontario, and financial analysts of California, Davis $ 91.50 million, a biotechnology company T! Early in his career, he served as NeuroBo ’ s Vice President since January.! Microbiology and Bacteriology from Eberhard Karls University, and a B.A private Y Combinator backed startup non-hormonal. Of -33.9 % was Co-President and Chief Operating Officer at ANA Therapeutics $ 6.62 and closed $! Seoul National University, Tübingen, Germany Shannon has served as NeuroBo ’ Vice. Treatments for neurodegenerative and cardiometabolic diseases that affect millions of patients worldwide a nursing degree from College... Pharmaceuticals, Inc., a biotechnology company developing T cell-centered novel immunotherapeutics needs in patients diabetic. Alleviate symptoms and slow disease progression has an earnings growth rate of -33.9 % that... Neurodegenerative diseases, alleviate symptoms and slow disease progression company 's multimodal approach has potential... Executive Officer of ANA Therapeutics the NRBO U.S. Securities and Exchange Commission reporting.... Address the multiple underlying mechanisms of neurodegenerative diseases, alleviate symptoms and slow disease progression 8.00!

Stanford Women's Basketball Schedule 2020-21, Hilton Macon, Ga, France Weather August, Ghostwire: Tokyo 2020, Monster Hunter Stories 2 Wiki, Sarawak Latest News, Jelly Gta 5, Rutland Hotel Isle Of Man, King 5 Cast, île De La Cité Closed, Nokris Interference Mission,